

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO Box 1450 Alexasofan, Virginia 22313-1450 www.repto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/591,831	10/23/2006	Berta Kotar-Jordan	4061-34PUS	4625	
27799 COHEN, PONTANI, LIEBERMAN & PAVANE LLP 551 FIFTH AVENUE			EXAM	EXAMINER	
			COLEMAN, BRENDA LIBBY		
SUITE 1210 NEW YORK.	NY 10176		ART UNIT	PAPER NUMBER	
,			1624		
			MAIL DATE	DELIVERY MODE	
			03/11/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/591,831 KOTAR-JORDAN ET AL. Office Action Summary Examiner Art Unit Brenda L. Coleman 1624 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 30 December 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-24 and 26-32 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) 1-8 and 26-32 is/are allowed. 6) Claim(s) 9-11,15,16 and 18-24 is/are rejected. 7) Claim(s) 12-14 and 17 is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date

Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)

Attachment(s)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

5) T Notice of Informal Patent Application

Application/Control Number: 10/591,831 Page 2

Art Unit: 1624

DETAILED ACTION

Claims 1-24 and 26-32 are pending in the application.

This action is in response to applicants' amendment dated December 30, 2009.

Claims 1, 9, 13, 19, 23, 24, 27 and 29 have been amended and claim 25 has been canceled.

Response to Amendment

Applicant's amendments filed December 30, 2009 have been fully considered with the following effect:

- 1. The applicants' amendments and arguments are sufficient to overcome the 35 U.S.C. § 112, second paragraph rejections labeled paragraph 1a), b), c), e) and f) in the last office action, which are hereby withdrawn. However, with regards to the 35 U.S.C. § 112, second paragraph rejections labeled paragraph 1d) in the last office action, the applicant's amendments have been fully considered but they are not persuasive.
 - d. The applicants' stated that the claims have been amended to be more definite. However, Claim 23 fails to set forth the metes and bounds of the claim, i.e. "a solvate or hydrate form of olanzapine".

Claim 23 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above.

The applicants' amendments and arguments are sufficient to overcome the 35 U.S.C. § 101, rejection labeled paragraph 2) in the last office action, which is hereby withdrawn.

Application/Control Number: 10/591,831

Art Unit: 1624

3. With regards to the provisional obviousness-type double patenting rejection as being unpatentable over claims 1-5 of copending Application No. 10/521,646 of the last office action, the applicants requested that this rejection be held in abeyance at this time

Claims 9-11, 15, 16 and 18-24 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5 of copending Application No. 10/521,646, for reasons of record and stated above.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

In view of the amendment dated December 30, 2009, the following new grounds of rejection apply:

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claim 23 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for salt forms, does not reasonably provide enablement for solvates. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. The claim is drawn to solvates. But the numerous examples presented all failed to produce a solvate. These cannot be simply willed into existence. As was stated in Morton International Inc. v. Cardinal Chemical

Art Unit: 1624

Co., 28 USPQ2d 1190 "The specification purports to teach, with over fifty examples, the preparation of the claimed compounds with the required connectivity. Hence, applicants must show that solvates can be made, or limit the claims accordingly.

Claim Objections

 Claims 12-14 and 17 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Allowable Subject Matter

6. Claims 1-8 and 26-32 are allowed. None of the prior art of record or a search in the pertinent art area teaches the isopropanol/water mixed solvate of olanzapine or the process of preparing form I olanzapine wherein the olanzapine form I is crystallized or precipitated from a liquid medium which medium is present in a container wherein the surfaces of the container contacting the medium are comprising at least one polymer.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for Application/Control Number: 10/591,831 Page 5

Art Unit: 1624

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Brenda L. Coleman/ Primary Examiner, Art Unit 1624